Beta Bionics Reports Strong Q2 Earnings with Sales Growth and Margin Expansion
Beta Bionics (NASDAQ:BBNX) reported second-quarter net sales of $32 million in the quarter ended June 30, a year-over-year increase of approximately 38%. The growth was driven by new patient starts for its iLet insulin-delivery system and recurring revenue from pharmacy-channel supply. Gross margin improved to 59.0%, up over five percentage points compared to last year, leading management to raise full-year gross-margin guidance to between 58.5% and 59.5%. The company also reaffirmed its annual revenue forecast of $131 million–$136 million. Beta Bionics expanded its sales force by at least 20 territories in the first half, aiming for stronger patient acquisition later this year. It maintained a cash balance of approximately $225 million and expects operating expenses to rise modestly as it invests in commercial growth and product development. The company is preparing for an FDA-cleared launch of its Mint patch pump by late Q2 2027, while also advancing clinical trials for iLet in Type 2 diabetes and next-generation closed-loop systems.
Tickers: $BBNX